Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Q3UL
|
||||
| Former ID |
DPR000090
|
||||
| Drug Name |
PD-160170
|
||||
| Synonyms |
NCGC00092332-01; BRD-K12079898-001-01-8; 5-nitro-6-(2-propan-2-ylphenyl)sulfonyl-quinolin-8-amine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hypertension; Obesity; Heart disease [ICD9: 278, 390-429; ICD10:E66, I00-I52] | Preclinical | [1] | ||
| Company |
Parke CDavis
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H17N3O4S
|
||||
| Canonical SMILES |
CC(C)C1=CC=CC=C1S(=O)(=O)C2=C(C3=C(C(=C2)N)N=CC=C3)[N+]<br />(=O)[O-]
|
||||
| InChI |
1S/C18H17N3O4S/c1-11(2)12-6-3-4-8-15(12)26(24,25)16-10-14(19)17-13(7-5-9-20-17)18(16)21(22)23/h3-11H,19H2,1-2H3
|
||||
| InChIKey |
YUVNGBZROXQYQH-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 181468-88-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Neuropeptide Y receptor type 1 | Target Info | Antagonist | [1] | |
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| NetPath Pathway | FSH Signaling Pathway | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| Endothelin Pathways | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.